+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ADMA Biologics Inc (ADMA) - Financial and Strategic SWOT Analysis Review

ADMA Biologics Inc (ADMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ADMA Biologics Inc (ADMA Biologics) is a biopharmaceutical company. It develops, produces, and commercializes specialty biologics to treat immune deficiencies and prevent certain infectious diseases. The company's product portfolio includes Bivigam, an Intravenous Immune Globulin (IVIG) product for the treatment of Primary Immunodeficiency Disease (PIDD), Asceniv, an IVIG product for the treatment of PIDD in adults and adolescents and Nabi-HB, for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg) and other listed exposures to Hepatitis B. It also operates plasma collection facilities that carry out plasma collection and offer blood plasma to manufacture the products. ADMA Biologics is headquartered in Ramsey, New Jersey, the US.

ADMA Biologics Inc Key Recent Developments

  • Feb 28, 2024: ADMA Biologics Announces CFO Transition
  • Nov 16, 2023: ADMA Biocenters Receives FDA Approval for Its Tenth Plasma Collection Center, Located in Laurel, MD
  • May 10, 2023: ADMA Biologics announces first quarter 2023 financial results and provides business update
  • Mar 23, 2023: ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • ADMA Biologics Inc - Key Facts
  • ADMA Biologics Inc - Key Employees
  • ADMA Biologics Inc - Key Employee Biographies
  • ADMA Biologics Inc - Major Products and Services
  • ADMA Biologics Inc - History
  • ADMA Biologics Inc - Company Statement
  • ADMA Biologics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • ADMA Biologics Inc - Business Description
  • Business Segment: ADMA BioManufacturing
  • Overview
  • Performance
  • Business Segment: Corporate
  • Overview
  • Performance
  • Business Segment: Plasma Collection Centers
  • Overview
  • Performance
  • Geographical Segment: International
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • ADMA Biologics Inc - Corporate Strategy
  • ADMA Biologics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • ADMA Biologics Inc - Strengths
  • ADMA Biologics Inc - Weaknesses
  • ADMA Biologics Inc - Opportunities
  • ADMA Biologics Inc - Threats
  • ADMA Biologics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • ADMA Biologics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 28, 2024: ADMA Biologics Announces CFO Transition
  • Nov 16, 2023: ADMA Biocenters Receives FDA Approval for Its Tenth Plasma Collection Center, Located in Laurel, MD
  • May 10, 2023: ADMA Biologics announces first quarter 2023 financial results and provides business update
  • Mar 23, 2023: ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
  • Mar 16, 2023: ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • ADMA Biologics Inc, Key Facts
  • ADMA Biologics Inc, Key Employees
  • ADMA Biologics Inc, Key Employee Biographies
  • ADMA Biologics Inc, Major Products and Services
  • ADMA Biologics Inc, History
  • ADMA Biologics Inc, Subsidiaries
  • ADMA Biologics Inc, Key Competitors
  • ADMA Biologics Inc, Ratios based on current share price
  • ADMA Biologics Inc, Annual Ratios
  • ADMA Biologics Inc, Interim Ratios
  • ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • ADMA Biologics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • ADMA Biologics Inc, Performance Chart (2019 - 2023)
  • ADMA Biologics Inc, Ratio Charts
  • ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Shire Pharmaceuticals International UC
  • Octapharma AG
  • Grifols Biologicals Inc
  • Enanta Pharmaceuticals Inc
  • Anacor Pharmaceuticals Inc
  • Almirall LLC
  • CSL Behring LLC
  • Kedrion SpA
  • GlycoMimetics Inc
  • Global Life Sciences Solutions USA LLC